Correlation Between Scopus Biopharma and Magenta Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Scopus Biopharma and Magenta Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Scopus Biopharma and Magenta Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Scopus Biopharma and Magenta Therapeutics, you can compare the effects of market volatilities on Scopus Biopharma and Magenta Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Scopus Biopharma with a short position of Magenta Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Scopus Biopharma and Magenta Therapeutics.

Diversification Opportunities for Scopus Biopharma and Magenta Therapeutics

-0.53
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Scopus and Magenta is -0.53. Overlapping area represents the amount of risk that can be diversified away by holding Scopus Biopharma and Magenta Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Magenta Therapeutics and Scopus Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Scopus Biopharma are associated (or correlated) with Magenta Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Magenta Therapeutics has no effect on the direction of Scopus Biopharma i.e., Scopus Biopharma and Magenta Therapeutics go up and down completely randomly.

Pair Corralation between Scopus Biopharma and Magenta Therapeutics

If you would invest  82.00  in Magenta Therapeutics on September 3, 2024 and sell it today you would earn a total of  0.00  from holding Magenta Therapeutics or generate 0.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Scopus Biopharma  vs.  Magenta Therapeutics

 Performance 
       Timeline  
Scopus Biopharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Scopus Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Scopus Biopharma is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors.
Magenta Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Magenta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Magenta Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Scopus Biopharma and Magenta Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Scopus Biopharma and Magenta Therapeutics

The main advantage of trading using opposite Scopus Biopharma and Magenta Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Scopus Biopharma position performs unexpectedly, Magenta Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Magenta Therapeutics will offset losses from the drop in Magenta Therapeutics' long position.
The idea behind Scopus Biopharma and Magenta Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Other Complementary Tools

Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities